Royalty Pharma plc
- Last sale
- Nov 12, 2026 · -1.46%
- Market cap
- $39.56B
- 573.61M shares
- Filings
- 643
Q3 2026+5.1% FY25 yoy
Q3 2026−10.2% FY25 yoy
Q3 2026+20.7% FY25 yoy
—
—
—Q3 2026−6.8% FY25 yoy
Q3 2026−33.4% FY25 yoy
- $39.56B
- 58.8×
- 15.1×
- 4.0×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2,378,193,000 | reported | |
| FY 2024 | 2024-12-31 | $2,263,576,000 | reported | |
| FY 2023 | 2023-12-31 | $2,354,554,000 | reported | |
| FY 2022 | 2022-12-31 | $2,237,215,000 | reported | |
| FY 2021 | 2021-12-31 | $2,289,463,000 | reported | |
| FY 2020 | 2020-12-31 | $2,122,353,000 | reported | |
| FY 2019 | 2019-12-31 | $1,814,254,000 | reported | |
| FY 2018 | 2018-12-31 | $1,794,894,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $1.23B | $1.23B | — | — | — | — |
| FY2024 | — | $229.65M | $229.65M | $0.84 | — | — | — |
| FY2023 | — | $304.76M | $304.76M | $0.80 | — | — | — |
| FY2022 | — | $0.00 | $0.00 | $0.76 | — | — | — |
| FY2021 | — | $0.00 | $0.00 | $0.68 | — | — | — |
Segments
Products
LineFY2025ShareChange
Income from financial royalty assets$2.26B95%+5.2%
Other royalty income and revenues$117.04M4.9%+2.5%
Revenue from intangible royalty assets———
Total$2.38B
Pharmaceutical preparations
Royalty Pharma plc is the 26th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
GMABGenmab A/S$3.7B19.2%25.9%—ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BBMRNBioMarin Pharmaceutical Inc$3.2B12.9%10.8%$11.0BUTHRUnited Therapeutics Corp$3.2B10.6%41.9%$25.3BAMRXAmneal Pharmaceuticals, Inc.$3.0B8.0%2.4%$7.5B
RPRXRoyalty Pharma plc (this company)$2.4B5.1%32.4%$39.6B
SRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BPTCTPTC Therapeutics, Inc.$1.7B114.5%39.4%$5.3BPAHCPhibro Animal Health Corp$1.5B17.1%6.6%$1.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Royalty Pharma plc · CIK 1802768 · Engraved from SEC EDGAR